We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Noting that many of the pharmaceutical industry's best-selling products will soon lose their patent protection, industry analysts have reportedly suggested that the potential loss of nearly one-third of industry revenues in the near term could account for recent merger activity among the world's largest pharmaceutical companies
Quebec's Charest administration has reportedly launched the third of three new venture capital funds to provide more than $41 million for investment in biotechnology research
The U.K. Panel on Takeovers and Mergers has announced that it plans to amend the Takeover Code to reduce the tactical advantage that hostile offerors have under the current code, particularly when short-term investors unduly influence the outcome of hostile offers to the detriment of the offeree company and its shareholders
Sinochem Group, a China-based oil and chemicals company, has announced an agreement with Royal DSM N.V., a Dutch global life sciences and material sciences company, to form a global anti-infective joint venture to be headquartered in Hong Kong
While five venture-capital backed biotech companies have reportedly gone public in 2011, each has been forced to lower its offering price even before the initial public offering took place due to weakened demand
According to an SVP Financial Group report, contrary to conventional wisdom, biotech exits occur faster than device exits and have lower, but solid, multiples on invested capital
Cincinnati-based CincyTech, a venture development company that invests in startup biotech, information technology and advanced manufacturing businesses, has announced the closing of a $4.4 million Fund II targeted for 10 to 12 new startups in southwest Ohio
After conducting its yearly survey of media reports, a North Carolina trade association has announced that life sciences companies brought in more than $1.1 billion in investments and grants to the state in the 12 months ending April 25, 2011, representing a 25 percent increase over the 12-month period ending April 2010
